Motexafin gadolinium
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C52H72GdN5O14 |
| Molar mass | 1148.42 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Motexafin gadolinium (proposed tradename Xcytrin) is an inhibitor of thioredoxin reductase and ribonucleotide reductase. It has been proposed as a possible chemotherapeutic agent in the treatment of brain metastases.[1]
History
[edit]On May 9, 2006, a New Drug Application was submitted to the United States Food and Drug Administration (FDA) by Pharmacyclics, Inc.[2]
In December 2007, the FDA issued a not approvable letter for motexafin gadolinium.[3]
References
[edit]- ^ Richards G, Mehta M (2007). "Motexafin gadolinium in the treatment of brain metastases". Expert Opinion on Pharmacotherapy. 8 (3): 351–9. doi:10.1517/14656566.8.3.351. PMID 17266469. S2CID 25542776.
- ^ Pharmacyclics, Inc. press release - Pharmacyclics to Submit New Drug Application for Xcytrin for Treatment of Lung Cancer Patients With Brain Metastases
- ^ Pharmacyclics, Inc. press release - Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases
.svg){kind=small} | This biochemistry article is a stub. You can help Wikipedia by expanding it. |